ZNTL
ZentalisCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The bull case is that May 2026 company disclosures showed tangible forward progress: pivotal dose selection for azenosertib, ASPENOVA initiation, and runway into late 2027, which together keep the accelerated-approval thesis alive ahead of the DENALI readout [#SEC-8K-2026-05-12].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +4.5.
What can break
Clinical readout risk is dominant because DENALI Part 2 remains the main binary value event for azenosertib.
Momentum
93
Value
41
Sentiment
29
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.50 · Bull $6.50 · Bear $1.80
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $6.75
Why
Momentum93 · Δ7d +4.5
Value41 · Δ7d +0.0
Sentiment29 · Δ7d -6.5
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
93
26% active weight
Current posture
7d trendImproving
Δ7d
+4.5
Δ21d
+11.2
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
29
34% active weight
Current posture
7d trendSoftening
Δ7d
-6.5
Δ21d
-22.8
Why this grade
Composite grade C. Momentum 93.4 / Value 41.1 / Sentiment 28.9
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$356.64M
Beta
1.71
Shares Out
71.19M
P/E (TTM) · Derived
-2.6
P/S (TTM)
3.68
P/FCF (TTM) · Derived
-2.85
Rev YoY
-100.0%
EPS YoY
-25.3%
Gross Margin
+96.7%
Op Margin
-615.2%
Net Debt
-$206.32M
Current Ratio
6.19
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology